By Fineline Cube Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a license agreement with SynuSight BioTech for the innovative PET tracer SST001, a proprietary molecular imaging agent targeting α‑synuclein (α‑syn). Under the deal, Mabwell gains exclusive rights in Greater China to develop the tracer for the diagnosis and treatment of Parkinson’s disease (PD) and multiple system atrophy (MSA), extending the antibody specialist’s reach into neurological molecular imaging.
Deal Structure
| Item | Detail |
|---|---|
| Licensee | Mabwell (SHA: 688062; HKG: 2493) |
| Licensor | SynuSight BioTech |
| Asset | SST001, PET molecular tracer targeting α‑synuclein |
| Territory | Greater China (Hong Kong, Macau, and Taiwan) |
| Exclusivity | Exclusive license |
| Date | 31 Aug 2026 |
Financial Terms
| Component | Amount / Rate |
|---|---|
| Upfront Payment | RMB 20 million |
| Milestone – Phase 3 Initiation | RMB 8 million |
| Milestone – Marketing Authorization | RMB 12 million |
| Royalties | 4.3% of net sales following first commercial sale |
Asset Profile – SST001
- Modality: Proprietary PET molecular tracer
- Target: α‑synuclein (α‑syn), the pathological protein hallmark of synucleinopathies
- Intended Utility: Clinical trials to evaluate use in diagnosis and treatment of Parkinson’s disease and multiple system atrophy
- Differentiation: Direct imaging of α‑synuclein pathology addresses a critical gap — current PD diagnostics rely largely on clinical assessment and dopaminergic imaging rather than disease‑specific biomarkers
- Development Stage: Planned clinical trial program to be conducted by the parties under the agreement
The transaction pairs SynuSight‘s radiotracer discovery capability with Mabwell‘s clinical development and commercialization infrastructure in Greater China. For SynuSight, the deal converts an early‑stage neuroscience asset into near‑term cash and milestone economics; for Mabwell, it diversifies the portfolio beyond monoclonal antibodies into the fast‑emerging neurodegenerative diagnostics space.
Market Impact & Outlook
- Neuro Diagnostics Frontier: α‑synuclein PET imaging is among the most sought‑after tools in neurology, with no approved tracer currently able to directly visualize synuclein pathology in living patients
- Strategic Diversification: The license expands Mabwell’s pipeline adjacency into CNS imaging and theranostics while preserving its antibody core
- Regional Focus: Greater China exclusivity aligns with rising demand for early and differential diagnosis of Parkinsonian syndromes in an aging population
- Deal Economics: Modest upfront with milestone and royalty structure reflects early‑stage risk sharing, while preserving upside if SST001 validates in pivotal trials
Forward‑Looking Statements — This brief contains forward‑looking statements regarding the development, regulatory progress, and commercialization of SST001 under the Mabwell–SynuSight agreement. Actual results may differ materially due to risks inherent in drug development, regulatory review, and competitive dynamics. Readers should not place undue reliance on such statements.-Fineline Info & Tech